All Outputs (3)

Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study (2022)
Journal Article
Vijay, A., Al-Awadi, A., Chalmers, J., Balakumaran, L., Grove, J. I., Valdes, A. M., Taylor, M. A., Shenoy, K. T., & Aithal, G. P. (2022). Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study. Nutrients, 14(14), Article 2808. https://doi.org/10.3390/nu14142808

Background: Non-alcoholic fatty liver disease (NAFLD) is a global problem growing in parallel to the epidemics of obesity and diabetes, with South Asians being particularly susceptible. Nutrition and behaviour are important modifiers of the disease,... Read More about Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study.

HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19 (2022)
Journal Article
Astbury, S., Reynolds, C. J., Butler, D. K., Munoz-Sandoval, D. C., Lin, K., Pieper, F. P., …Altmann, D. M. (2022). HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19. Immunology, 166(1), 68-77. https://doi.org/10.1111/imm.13450

SARS-CoV-2 infection results in different outcomes ranging from asymptomatic infection to mild or severe disease and death. Reasons for this diversity of outcome include differences in challenge dose, age, gender, comorbidity and host genomic variati... Read More about HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19.

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022)
Journal Article
Lee, K. A., Thomas, A. M., Bolte, L. A., Björk, J. R., de Ruijter, L. K., Armanini, F., …Segata, N. (2022). Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nature Medicine, 28(3), 535-544. https://doi.org/10.1038/s41591-022-01695-5

The composition of the gut microbiome has been associated with clinical responses to immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on the specific microbiome characteristics linked to the clinical benefits of ICIs. We pe... Read More about Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.